Accelerated/blast phase MPN pre-transplant bridging

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-09-21 — Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN: cross-connection with astx727-venetoclax-cmml-mds-mpn: Metronomic ASTX727 + venetoclax extends the oral HMA + BCL-2 backbone into high-risk/accelerated-phase MPN, a population overlapping with the AP/BP-MPN bridging-to-transplant setting. (novelty: 3)
• 2026-07-01 — Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms: cross-connection with pacritinib-venetoclax-azacitidine-ap-bp-mpn: The new pacritinib + venetoclax + azacitidine triplet is positioned within the emerging AP/BP-MPN bridging landscape, potentially serving as an intensified alternative to JAK inhibitor + HMA doublets for patients pre-transplant. (novelty: 4)
• 2026-05-15 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse: cross-connection with decitabine-flag-ida-tbi-conditioning: Both address pre-allo-HSCT cytoreduction in high-risk myeloid disease; decitabine + FLAG-Ida + TBI represents an intensified conditioning approach distinct from chemo-sparing HMA + JAKi bridging strategies. (novelty: 3)
• 2026-03-04 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms: Phase II trial (trial-early) directly evaluating pacritinib + azacitidine or decitabine as pre-transplant bridging in AP/BP-MPN, with the primary endpoint being the proportion of patients successfully proceeding to allogeneic HSCT — establishes a defined bridging regimen for this underserved population. (novelty: 3)

Open questions

Related